Search research articles
Contact Us
Filters
Showing results (611-620 of 631) with videos related to
Page
of 64
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
T André, D Vernerey, S A Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2024
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
T André, K-K Shiu, T W Kim, et al.
ESMO Open
|
May 7, 2025
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J Taieb, J Seligmann, D Modest, et al.
Clinical Colorectal Cancer
|
March 21, 2023
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
P Jiménez-Fonseca, J Sastre, P García-Alfonso, et al.
Nature
|
January 22, 2016
Inter-group violence among early Holocene hunter-gatherers of West Turkana, Kenya
M Mirazón Lahr, F Rivera, R K Power, et al.
Nature
|
November 25, 2016
Mirazón Lahr et al. reply
M Mirazón Lahr, F Rivera, R K Power, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
January 27, 2023
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
M Toledano-Fonseca, M A Gómez-España, E Élez, et al.
ESMO Open
|
March 12, 2021
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
J Sastre, P García-Alfonso, J M Viéitez, et al.
Nature Communications
|
March 22, 2023
Pan-genome inversion index reveals evolutionary insights into the subpopulation structure of Asian rice
Yong Zhou, Zhichao Yu, Dmytro Chebotarov, et al.
Annual Review of Phytopathology
|
August 29, 2018
World Management of Geminiviruses
Maria R Rojas, Monica A Macedo, Minor R Maliano, et al.
Page
of 64
Search research articles
Search
Showing results (611-620 of 631) with videos related to
Sort By:
Page
of 64
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
T André, D Vernerey, S A Im, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2024
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
T André, K-K Shiu, T W Kim, et al.
ESMO Open
|
May 7, 2025
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative
J Taieb, J Seligmann, D Modest, et al.
Clinical Colorectal Cancer
|
March 21, 2023
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
P Jiménez-Fonseca, J Sastre, P García-Alfonso, et al.
Nature
|
January 22, 2016
Inter-group violence among early Holocene hunter-gatherers of West Turkana, Kenya
M Mirazón Lahr, F Rivera, R K Power, et al.
Nature
|
November 25, 2016
Mirazón Lahr et al. reply
M Mirazón Lahr, F Rivera, R K Power, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
January 27, 2023
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
M Toledano-Fonseca, M A Gómez-España, E Élez, et al.
ESMO Open
|
March 12, 2021
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
J Sastre, P García-Alfonso, J M Viéitez, et al.
Nature Communications
|
March 22, 2023
Pan-genome inversion index reveals evolutionary insights into the subpopulation structure of Asian rice
Yong Zhou, Zhichao Yu, Dmytro Chebotarov, et al.
Annual Review of Phytopathology
|
August 29, 2018
World Management of Geminiviruses
Maria R Rojas, Monica A Macedo, Minor R Maliano, et al.
Page
of 64